Seeking for effective drugs which are beneficial to facilitating axonal regrowth and elongation after peripheral nerve injury (PNI) has gained extensive attention. Fibroblast growth factor 21 (FGF21) is a metabolic factor that regulates blood glucose and lipid homeostasis. However, there is little concern for the potential protective effect of FGF21 on nerve regeneration after PNI and revealing related molecular mechanisms. Here, we firstly found that exogenous FGF21 administration remarkably promoted functional and morphologic recovery in a rat model of sciatic crush injury, manifesting as persistently improved motor and sensory function, enhanced axonal remyelination and regrowth and accelerated Schwann cells (SCs) proliferation. Furthermore, local FGF21 application attenuated the excessive activation of oxidative stress, which was accompanied with the activation of nuclear factor erythroid-2-related factor 2 (Nrf-2) transcription and extracellular regulated protein kinases (ERK) phosphorylation. We detected FGF21 also suppressed autophagic cell death in SCs. Additionally, treatment with the ERK inhibitor U0126 or autophagy inhibitor 3-MA partially abolishes anti-oxidant effect and reduces SCs death. Taken together, these results indicated that the role of FGF21 in remyelination and nerve regeneration after PNI was probably related to inhibit the excessive activation of ERK/Nrf-2 signalling-regulated oxidative stress and autophagy-induced cell death. Overall, our work suggests that FGF21 administration may provide a new therapy for PNI.
Moreover, such injuries affect more than 20 million people annually in the United States alone. 1 Damage to the peripheral nerves may result in motor and sensory dysfunction and irreversible tissue atrophy. 2, 3 Although the adult mammalian peripheral nervous system has a considerable potential for spontaneous recovery, the complex and chronic recovery process often leads to unsatisfactory repair results. 4 At present, direct surgical repair, nerve grafting and nerve bridging are still regarded as the golden standard therapeutic approaches for peripheral nerve rehabilitation. 5 However, those surgical operations have several disadvantages, including need for a second operation, insufficient nerve donors and possible formation of neurofibroma around the focal area. 2, 4 Therefore, seeking novel drug therapy to overcome these shortcomings has become very essential. 6, 7 Molecular therapy utilizing fibroblast growth factors (FGFs) to promote peripheral nerve myelination and regrowth has been used almost universally. 8 FGFs are a family of cell signalling molecules involved in comprehensive biological properties and participate in regulating cell differentiation, proliferation and metabolism. 9, 10 As one member of those family, fibroblast growth factor 21 (FGF21) exerts pleiotropic effects on modulating glucose, lipid and energy homeostasis. 11, 12 It is mainly secreted by the liver, pancreas, kidney, skeletal muscle and fat. 13 Studies on obese rodents have demonstrated that administration of recombinant FGF21 significantly reduced hyperglycemia and hepatic triglyceride concentration, improved energy expenditure and alleviated insulin resistance. 14, 15 Apart from its metabolic regulation, recently, there is increasing evidence indicating that FGF21 possesses protective effects on myocardial ischaemia and neurotrauma. 16, 17 For example, Planavila et al.
have identified FGF21 protected the heart from ischaemia-reperfusion via controlling oxidative stress signalling. 18 FGF21 is also a key mediator for glutamate-induced excitotoxicity and D-galactoseinduced ageing in the central nervous system (CNS). 19, 20 Furthermore, it is reported that circulating FGF21 levels increased the injury lesion to promote remyelination after traumatic brain injury. 21 However, little work has been done to explore FGF21 on nerve regeneration after PNI and clarify its underlying mechanisms.
Oxidative stress is a highly disordered metabolic process that generates the imbalance between oxides and antioxidants. 22 Peripheral nerves are susceptible to oxidative stress, and it has been reported that reactive oxygen species (ROS) production showed a significant increase after PNI. 23 Once the peripheral nerve suffered damage, the lesion site and its distal stump are accompanied by extensive ischaemic and inflammatory processes, resulting in a redundant accumulation of ROS. At the same time, the levels of endogenous antioxidants, including superoxide dismutase (SOD), NADH dehydrogenase quinone 1 (NQO1) and Heme oxygenase-1 (HO-1), are not sufficient to maintain the requirement for resisting oxidative damage in the trauma region, which finally result in cell apoptosis and death. [24] [25] [26] In the antioxidant defensive system, Nuclear factor erythroid 2-related factor 2 (Nrf-2) as a pivotal transcription factor for regulating oxidative stress, is able to translocate into the nucleus after separating from Kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm to initiate transcription of antioxidant genes including NQO1 and HO-1 to recover cellular normal physiological function. 27, 28 As one of upstream signal for regulating Nrf-2, extracellular-regulated protein kinase (ERK) is a serinethreonine kinase that participates in the modulation of cell proliferation, differentiation and cytoskeletal dynamics. 29 After PNI, ERK activates the downstream pathway of Nrf-2 to promote SC proliferation and nerve repair. 30, 31 In addition, the ERK/Nrf-2 signalling pathway ameliorates diabetic neuropathy induced-oxidative damage. 32 Thus, we speculate that ERK/Nrf-2-mediated antioxidative process may be the potential molecular mechanism for regulating FGF21 neuroprotective property.
Autophagy is an intracellular catabolic progression that degrades the certain amounts of waste proteins or damage organelles in double-membraned vesicles to maintain metabolize homeostasis. During the last decade, autophagy has been found to be strongly connected with nervous system disease. 33 Generally, moderate autophagy is regarded as the neuroprotective effect. However, an excessive level of autophagy may lead to nonapoptotic cell death, which is known as autophagic cell death. 34 Various studies have been shown that abnormal autophagy activation aggravated neurotraumatic disease such as ischaemia stroke, traumatic brain injury (TBI) and acute spinal cord injury. [35] [36] [37] Using autophagic inhibitor 3-methyladenine (3-MA) or knockout autophagy-related gene could decrease those neurotrauma-induced cell death. 38 Shi et al have reported that miR-195 increased inflammation-induced neuropathic pain by controlling microglial autophagy activation following PNI. 39 However, whether the effect of FGF21 on regulating neuroprotection is associated with suppressing autophagic cell death remains to be elucidated.
In this study, we systematically evaluated the role of FGF21 in axonal regeneration and remyelination and revealed its molecular mechanism following clip compression induced PNI. Our results found that exogenous administration of FGF21 enhanced the speed and extent of functional recovery, promoted nerve regrowth and remyelination, and facilitated SC proliferation. Moreover, this neuroprotective effect of FGF21 was related to the inhibition of excessive oxidative stress activation and autophagic cell death. The PNI model was described previously. 40 Briefly, after anaesthetizing by 10% chloral hydrate (3.5 mL/kg), all the rats were fixed on the operating 
| Walking track analysis
To evaluate motor function recovery, walking track analysis was performed on all the rats at 1, 2, 3, and 4 weeks postsurgery as previously described. 40 The trained rats walked through a confined glass box (90 cm × 15 cm × 20 cm) which placed a white paper 
| Cell viability assay

| Immunofluorescence staining
The immunofluorescent process of tissue or cells was done as previously described. 40, 43 The detailed information of primary and sec- 
| Western blotting analysis
Total proteins were extracted using RIPA buffer containing protease and phosphatase inhibitors for the surgical sciatic nerves or RSC96 cells. The protein concentration was quantitatively analysed, using a BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL, USA).
Samples containing 80 μg total protein were separated from 10% or 12% SDS-polyacrylamide gels and transferred into the nitrocellulose membrane PVDF (Bio-Rad, Hercules, CA, USA). After blocking with 5% nonfat milk, the membranes were incubated with the following (1:10000; MultiSciences, 70-Mab5465-100) was used as an internal control. Signals were visualized and band density was quantified, using a ChemiDocXRS + imaging system (Bio-Rad Laboratories, Hercules, CA, USA). The above experiment was repeated three times. Overall, these observations suggest that exogenous administration of FGF21 is beneficial to improving the recovery of both motor and sensory function after crush injury.
| FGF21 enhances myelinated fibres regeneration after PNI
After the sciatic nerve injury, axon regeneration is the pivotal step for nerve restore. 44, 45 To evaluate the histologic changes of the injured SCs. 49 They are the main composition in mature and functional SCs.
The results showed that there was an increased GFAP positive expression after nerve injury, while stronger in the FGF21 group.
The S-100 and MBP production were significantly reduced in the PNI group. However, these circumstances were significantly reversed after localized FGF21 treatment ( Figure 3D -G, # P < 0.05). Taken together, all of those results suggest that FGF21 can facilitate the proliferation of SCs after PNI, which is beneficial to remyelination.
| FGF21 exerts antioxidative effect in SCs after
PNI through activating ERK/Nrf-2 signalling
As previously described, activation of oxidative stress may cause detrimental effects on the process of remyelination after PNI. 22, 50 To determine whether FGF21 protects injured nerves from damaged by increasing the antioxidant response, the protein expressing levels of NQO1 and HO-1 were detected through western blotting. The results showed that the lever of NQO1 and HO-1 were slightly increased after PNI when compared with the control group. It is noteworthy that ERK-suppressing excessive oxidative stress is regulated through Nrf-2. 51 To further determine whether FGF21
protected the injured nerves from oxidative damage was through ERK/Nrf-2 signalling pathway, the levers of Nrf-2, p-ERK and ERK were measured by western blotting. The results showed the Nrf-2 expression and the ratio of p-ERK/ERK were increased following PNI and their levels were further enhanced after treating FGF21
( Figure 4G -I, # P < 0.05). Thus, we propose that FGF21-exerting antioxidant effect is involved in the ERK/Nrf-2 signalling pathway.
| FGF21 suppresses autophagy-induced cell death after PNI
Excessive or prolonged autophagy may lead to neuronal cell death. 
| DISCUSSION
FGF21 is generally regarded as a potent metabolic regulator. 20 Larger numbers of researches are focus on its specific effects on controlling glucose and lipid homeostasis, energy metabolism, and insulin sensitivity. 53 However, in the present study, we are mainly concerned about the effect of FGF21 on mediating neuroprotection and neuranagenesis that tries to reveal its underlying molecular mechanism following PNI. These new discoveries of FGF21-regulating PNI are concluded as follows: (I) FGF21 is capable of strong neuroprotective effect on the peripheral nervous system (PNS), manifesting in improving functional recovery, promoting both axonal elongation and remyelination, and enhancing SCs proliferation; (II) this F I G U R E 5 FGF21 administration suppresses autophagy-induced cell death in vivo. A-D, Western blotting and quantification data of Atg-5, Beclin1 and LC3 II/I in each group. E-G, Western blotting and quantification data of Bax and Bcl-2 in each group. H, Quantification of Bax/Bcl-2 ratio in all groups. *P < 0.05, **P < 0.01 and ***P < 0.001 vs the sham group, # P < 0.05 and ## P < 0.01 vs the PNI group. All these data represent the means ± SEM, n = 3 neuroprotective of FGF21 is likely associated with enhancing antioxidative capable in SCs in the lesion region to preventing excessive ROS production, which is further regulated by ERK/Nrf-2 signalling; (III) blocking autophagic cell death is also another effective pathway for FGF21 exerting neuroprotective and neurodevelopmental effect after PNI.
As is known, axonal regrowth and remyelination after PNI is critical for reconstructing a functional nerve that can dominate their appropriate target tissues. 4 GFs are implicated as the potential therapeutic agents on neurotraumatic disease because of their multiple roles on triggering neuranagenesis, neurotrophy and angiogenesis. In PNS, the synthesis and secretion of GFs primarily come from SCs.
However, those endogenous GFs could not satisfy the demands for nerve regeneration. Therefore, supplying exogenous GFs in the injured area becomes necessary for nerve repairing. Previously studied have reported that acid fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF) and nerve growth factor (NGF) could promote Schwann cell (SC) survival and axonal outgrowth in vivo and in vitro. 54 could decrease the Blood-brain barrier (BBB) disruption and neuron apoptosis, improve neurofunctional behaviour after traumatic brain injury (TBI). 17 Kuroda, M group found that peripherally derived FGF21 was contributed to oligodendrocyte proliferation and remyelination when the CNS suffers from pathological damage. 21 Furthermore, exogenous FGF-21 protein could absolutely avoid ageing neurons to suffer glutamate-induced excitotoxicity. 20 However, it remains unknown that whether these neuroprotective effects of FGF21 on CNS are also potentially acted on pathological PNS disease.
In this study, for the first time, we explored FGF21 on peripheral nerve regeneration through exogenously administrating FGF21 in rat sciatic nerve crush model. We found that FGF21 treatment significantly improved both the speed and extent of recovery of motor and sensory function, as analysed by SFI and mechanical withdrawal response ( Figure 1 ). Moreover, we similarly observed FGF21 treatment remarkably ameliorated histological and morphological recovery through H&E and double-immunofluorescence staining, manifesting in newborn nerve fibers increasing and regenerative axon growing ( Figure 2 ). It has been reported that SCs proliferation is contributed to remyelination. 48, 58 To address this fact, we examined the expression of SCs-associated proliferative proteins and the status of myelin Previous studies showed that oxidative stress was identified to be responsible for the neuronal disease, including PNI and diabetic neuropathy. 59 accumulation of ROS were generated in SCs, which led to a significant reduction of cell viability. But these side-effects were largely ameliorated with the pretreatment of FGF21 ( Figure 6 ).
Consistently, we also observed adding FGF21 markedly enhanced the anti-oxidative capable in vivo and in vitro, manifesting in obvious increase levers of NOQ1 and HO-1, which were partially reversed by U0126 (Figures 4 and 6) . Furthermore, we detected HO-1 was nearly co-localized with S-100 in all groups, meaning the changes of oxidative stress occurred in SCs. Collectively, all of these results indicate that the depressed antioxidative capacity in SCs after PNI leads to the massive accumulation of ROS, which deteriorates injured nerve regrowth. FGF21 possess the strong antioxidant potential to inhibit ROS production and protect SCs from apoptosis.
Oxidative stress is regulated by various intracellular signalling cascades, including ERK/Nrf-2, PI3 K/AKT, and JAK/STAT pathways. 63, 64 Among them, ERK/Nrf-2 signalling is regarded as the pivotal molecular regulatory mechanism for combatting oxidative stressinduced neuronal damage. 51, 65, 66 Nrf-2 is a key anti-oxidant defender that cooperates with the antioxidant response element (ARE) to maintain normal oxidative levels. 67 Mounting evidences showed that a series of Nrf-2-medicated antioxidant processes were involved in the upstream of MEK/ERK regulating. 68, 69 For instance, acetyl-L-carnitine effectively protected hippocampal neurons from oxidative damage and mitochondrial dysfunction mainly through the ERK/Nrf-2 pathway. 70 There is increasing evidence manifested that ERK could activate the downstream transcription factor of Nrf-2 to promote SCs proliferation and nerve repair. 30, 31 Furthermore, the ERK/Nrf-2-mediated mechanism also resisted diabetic neuropathy induced-oxidative damage. 32 However, there is no clear evidence that confirmed whether FGF21-medicated anti-oxidative enhancing was closely related to ERK/Nrf-2 signalling after PNI. In the present work, we found that FGF21 treating prominently upregulated phosphorylation of ERK and activated Nrf-2 signalling pathway when compared with the PNI rats ( Figure 4 ). These results were also confirmed in the cell lever ( Figure 6 ). Additionally, U0126 markedly reversed the effect of FGF21 on ERK phosphorylation and Nrf-2 activation. Taken together, these findings suggest that FGF21 enhanced antioxidant capacity to promote remyelination is probably through activating the ERK/Nrf-2 pathway.
Autophagy is tightly linked to PNI. 71, 72 Abnormal autophagic activity contributes to neuronal nonapoptotic cell death, namely "autophagic cell death", which can be mostly reflected by the ratio of Bax and Bcl-2. 73, 74 Previous studies have demonstrated that autophagic cell death could be induced by oxidative stress. 75 Upregulating the autophagy lever caused by oxidative damage is detrimental to neural survival and proliferation. 76, 77 Suppression of excessive autophagic activation through pharmacological or genetic methods may be a novel target to reduce reactive zinc-induced neurons and astrocytes death and alleviate the brain infarction after ischaemia injury. 78, 79 These findings support the possibility that correcting autophagic dysfunction may be a potential therapeutic strategy for repairing nerve injury. In the current research, we found out the autophagy lever was excessive activation both in vivo and in vitro, which was significantly reversed after FGF21 or 3-MA administration ( Figures 5 and 7) . Similar results also appeared on the ratio of Bax/ Bcl-2. The evidence suggests that abnormal autophagy activation may bring about neuronal death, which is harmful to the injured nerve regeneration. However, FGF21 is able to inhibit autophagic cell death to promote neuronal regrowth and remyelination after PNI.
In conclusion, we firstly demonstrated that exogenous FGF21 administration facilitated SCs proliferation, nerve remyelination, and functional recovery after PNI. Furthermore, this beneficial effect of FGF21 on the injured nerve and restoration, and SCs survival is likely related to suppress excessive oxidative stressinduced cell apoptosis via the ERK/Nrf-2 signalling pathway and autophagic cell death ( Figure S2 ). However, we did not study the specific relationship between anti-oxidative effect and anti-autophagic effect regulated by FGF21. In this study, we demonstrated that FGF21 firstly promoted the expression of antioxidant enzymes when suffering from oxidative damage. Thereafter, FGF21 suppresses the excessively autophagy activated. Moreover, the extent of antioxidant capacity is higher than the inhibition effect of autophagy ( Figure S1 ). All in all, our results suggest FGF21 administration may be a potential useful therapeutic drug for repairing PNI.
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